The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Jason Hassenstab
Project Title: Psychological Well Being and Momentary Cognition
Date: February 22, 2023 at 11:21 pm
Request ID: S2304
Aim 1: To determine if day to day changes in cognition are related to well-being and whether this relationship can predict AD pathological burden and disease progression.
Aim 2:
Aim 3:
Aim 4:
Investigator: Tammie Benzinger
Project Title: F18 – Fluselenamyl Beta Amyloid PET Imaging for Alzheimer Disease
Date: February 3, 2023 at 2:45 pm
Request ID: S2303
Aim 1: Dosimetry – To assess the dosimetry and safety of F18-Fluselenamyl in healthy adult volunteers (n=8, recruited and scanning)
Aim 2: Proof of Concept: To assess F18-Fluselenamyl sensitivity for imaging Amyloid beta pathophysiology and conduct comparative analysis of PET imaging data using C11-PIB imaging in same participants. (n=36, 18 healthy (9 male and 9 female) with CDR 0 and 18 AD participants(9 M and 9 F) with CDR >=0.5)
Aim 3: Aim 3A: Aim 2 participants will be invited for a short term f/u to undergo repeat F18-Fluselenamyl ~1 month after baseline FSA scan (n=10)
Aim 4: Aim 3B: 18 participants from Aim 2 will have a longitudinal f/u visit ~18 months after the initial study visit to repeat Fluselenamyl, PIB, MRI scan.
Investigator: Brendan Lucey
Project Title: Acute effect of lemborexant on CSF amyloid-beta and tau
Date: January 24, 2023 at 11:47 am
Request ID: S2302
Aim 1: To test the hypothesis that treatment with lemborexant 25 mg will decrease the CSF pT181/T181 ratio compared to placebo (primary outcome).
Aim 2: Measure the effect of lemborexant on other CSF AD biomarkers such as pS202/S202, pT217/T217, and Aβ (secondary outcomes).
Aim 3:
Aim 4:
Investigator: Andrei Vlassenko and Manu Goyal
Project Title: White Matter Metabolism in the Context of Aging, White Matter Hyperintensities, and Alzheimer’s Disease
Date: January 23, 2023 at 5:02 pm
Request ID: S2301
Aim 1: Determine the quantitative topography of white matter metabolism (including glucose metabolism, oxygen metabolism, cerebral blood flow, and aerobic glycolysis in relation to structural/microstructural brain MRI in healthy young adults and older adults without white matter hyperintensities (WMH).
Aim 2: Determine the quantitative topography of white matter metabolism in cognitively unimpaired older adults with WMH. We will compare these data to those obtained in Aim 1.
Aim 3: Analyze brain MRIs in our existing cohort of adults who have previously undergone metabolic PET imaging.
Aim 4:
Investigator: Ilya E. Monosov
Project Title: High precision within subject reverse engineering of psychiatric disorders
Date: January 24, 2022 at 9:47 am
Request ID: S2105
Aim 1: High precision rapid online behavioral assay to reverse engineer maladaptive behavior within individual subjects
Aim 2: Uncovering precise behavioral variables that disrupt adaptive decision making and cognition
Aim 3: Relating identified disruptions in adaptive behavior to genetics
Aim 4:
Investigator: John Morris
Project Title: Phase III Elan Passive Immunization with ApoE 4 carriers
Date: December 21, 2021 at 5:29 pm
Request ID: S0817
Aim 1:
Aim 2:
Aim 3:
Aim 4:
Investigator: John Morris
Project Title: Phase III Elan Passive Immunization with ApoE 4 non-carriers
Date: December 21, 2021 at 5:29 pm
Request ID: S0818
Aim 1:
Aim 2:
Aim 3:
Aim 4:
Investigator: Lenze
Project Title: Escitalopram and cognitive behavioral therapy for the maintenance of response in late life GAD
Date: December 21, 2021 at 5:29 pm
Request ID: S0820
Aim 1:
Aim 2:
Aim 3:
Aim 4:
Investigator: Randall Bateman
Project Title: Human CNS Apoliproprotein E Isoform Production and Clearance
Date: December 21, 2021 at 5:29 pm
Request ID: S0819
Aim 1:
Aim 2:
Aim 3:
Aim 4:
Investigator: Morris/Benzinger
Project Title: Amyloid-beta Deposition in Aging: Quantitative Comparison of Two Amyloid Imaging Agents
Date: December 21, 2021 at 5:29 pm
Request ID: S1014
Aim 1: To add beta-amyloid plaque imaging with PET using AV-45 to the longitudinal assessments to KARI.
Aim 2:
Aim 3:
Aim 4: